A double blind, randomized, placebo controlled comparison of the efficacy, safety, and tolerability of celecoxib 100-150 mg, Including Initial Doses of 50 and 100 mg, and Placebo in the symptomatic treatment of patients with painful pharyngitis
Phase of Trial: Phase III
Latest Information Update: 01 Apr 2011
At a glance
- Drugs Celecoxib (Primary)
- Indications Pain
- Focus Therapeutic Use
- Sponsors Pfizer
- 10 Feb 2009 Patient number amended from 268 to 269 as reported by ClinicalTrials.gov.
- 04 Jun 2007 Status changed from recruiting to in progress.
- 28 Feb 2007 New trial record.